Hyeon Jeong Oh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Hyeon Jeong Oh has a total of 107 co-authors. Here are the top co-authors by number of shared publications:
- Jin Won Kim
Division of Hematology and Medical Oncology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Republic of Korea
16 shared publications - Keun-Wook Lee
Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Republic of Korea
16 shared publications - Ji-Won Kim
Division of Hematology and Medical Oncology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Republic of Korea
14 shared publications - Bo-Ram Park
Division of Hematology and Medical Oncology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Republic of Korea
13 shared publications - Eun Hee Jung
Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea
13 shared publications - Jee Hyun Kim
Division of Hematology and Medical Oncology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Republic of Korea
13 shared publications
Latest Publications
- Open Access
- 24 July 2026
- Published by The Editorial Office of Gut and Liver in Gut and Liver
- Vol. 20 (6) , 1026-1038
Sex Hormone Receptor Profiling Reveals an Association between Estrogen Receptor β-NRF2 Signaling and Improved Outcomes in Colorectal Cancer Patients
Yonghoon Choi, Nayoung Kim, Chin-Hee Song, Hyeon Jeong Oh. Gut and Liver -0001;0:. https://doi.org/10.5009/gnl250538
- 24 July 2026
- Published by The Editorial Office of Gut and Liver in Gut and Liver
- Vol. 20 (6) , 1026-1038
Open AccessSex Hormone Receptor Profiling Reveals an Association between Estrogen Receptor β-NRF2 Signaling and Improved Outcomes in Colorectal Cancer Patients
Yonghoon Choi, Nayoung Kim, Chin-Hee Song, Hyeon Jeong Oh. Gut and Liver -0001;0:. https://doi.org/10.5009/gnl250538
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Pertuzumab Enhances the Antitumor Activity of T-DXd in HER2-Positive Gastric Cancer Cells
Topoisomerase assay data related to Figure 2E. A) The doubling time and Mid-log Phase time for five HER2+ gastric cell lines (NUGC4, SNU216, MKN7, OE19, and NCI-N87). B) Representative uncropped gel of pUC19 plasmid DNA (0.5μg) treated with increasing units of recombinant topoisomerase 1 (TOPO1; 0, 0.5, 1, 2, 4, and 8 Units) and with 1μg of cytosolic and nuclear protein fractions prepared from NUGC4, SNU216, MKN7, OE19, and NCI-N87 cells. C) Representative uncropped gel of pUC19 plasmid DNA (1μg) treated with increasing TOPO1 (0, 0.5, 1, 2, 4, and 8 Units) and incremental amounts of nuclear protein (0.1, 0.5, 1 μg) from OE19 and NCI-N87 cells. Gels are presented in both the original format and in black and white inverted format to facilitate visualization of DNA bands.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Pertuzumab Enhances the Antitumor Activity of T-DXd in HER2-Positive Gastric Cancer Cells
Topoisomerase assay data related to Figure 2E. A) The doubling time and Mid-log Phase time for five HER2+ gastric cell lines (NUGC4, SNU216, MKN7, OE19, and NCI-N87). B) Representative uncropped gel of pUC19 plasmid DNA (0.5μg) treated with increasing units of recombinant topoisomerase 1 (TOPO1; 0, 0.5, 1, 2, 4, and 8 Units) and with 1μg of cytosolic and nuclear protein fractions prepared from NUGC4, SNU216, MKN7, OE19, and NCI-N87 cells. C) Representative uncropped gel of pUC19 plasmid DNA (1μg) treated with increasing TOPO1 (0, 0.5, 1, 2, 4, and 8 Units) and incremental amounts of nuclear protein (0.1, 0.5, 1 μg) from OE19 and NCI-N87 cells. Gels are presented in both the original format and in black and white inverted format to facilitate visualization of DNA bands.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from Pertuzumab Enhances the Antitumor Activity of T-DXd in HER2-Positive Gastric Cancer Cells
Uncropped western blot related to Figure 5A. Representative uncropped blots showing the expression of HER2 and HER3 in OE19 and NCI-N87 cells immunoprecipitated with anti-HER2 antibody. Input, IgG, and HER2 immunoprecipitates are shown in Figure 5A.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from Pertuzumab Enhances the Antitumor Activity of T-DXd in HER2-Positive Gastric Cancer Cells
Uncropped western blot related to Figure 5A. Representative uncropped blots showing the expression of HER2 and HER3 in OE19 and NCI-N87 cells immunoprecipitated with anti-HER2 antibody. Input, IgG, and HER2 immunoprecipitates are shown in Figure 5A.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Pertuzumab Enhances the Antitumor Activity of T-DXd in HER2-Positive Gastric Cancer Cells
Uncropped western blot related to Figure 2F. Representative uncropped blots showing the expression of p-CHK1 S345, CHK1, and γ-H2ax in OE19, and NCI-N87 cells following incubation with T-DXd (0, 2, 20, and 200 ng/mL) for 48 and 72h. The corresponding Vinculin loading controls are shown in Figure 2F.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Pertuzumab Enhances the Antitumor Activity of T-DXd in HER2-Positive Gastric Cancer Cells
Uncropped western blot related to Figure 2F. Representative uncropped blots showing the expression of p-CHK1 S345, CHK1, and γ-H2ax in OE19, and NCI-N87 cells following incubation with T-DXd (0, 2, 20, and 200 ng/mL) for 48 and 72h. The corresponding Vinculin loading controls are shown in Figure 2F.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from Pertuzumab Enhances the Antitumor Activity of T-DXd in HER2-Positive Gastric Cancer Cells
Uncropped western blot related to Figure 4A. Representative uncropped blots showing the expression of p-CHK1 S345, CHK1, and PARP in NCI-N87 cells for 48 h with the following treatments: lane 1, 0 ng/mL T-DXd and 0 μg/mL pertuzumab; lane 2, 20 ng/mL T-DXd and 0 μg/mL pertuzumab; lane 3, 0 ng/mL T-DXd and 20 μg/mL pertuzumab; lane 4, 20 ng/mL T-DXd and 20 μg/mL pertuzumab. The corresponding Vinculin loading controls are shown in Figure 2F.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from Pertuzumab Enhances the Antitumor Activity of T-DXd in HER2-Positive Gastric Cancer Cells
Uncropped western blot related to Figure 4A. Representative uncropped blots showing the expression of p-CHK1 S345, CHK1, and PARP in NCI-N87 cells for 48 h with the following treatments: lane 1, 0 ng/mL T-DXd and 0 μg/mL pertuzumab; lane 2, 20 ng/mL T-DXd and 0 μg/mL pertuzumab; lane 3, 0 ng/mL T-DXd and 20 μg/mL pertuzumab; lane 4, 20 ng/mL T-DXd and 20 μg/mL pertuzumab. The corresponding Vinculin loading controls are shown in Figure 2F.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Pertuzumab Enhances the Antitumor Activity of T-DXd in HER2-Positive Gastric Cancer Cells
Immunofluorescence of HER2 in SNU216 and MKN7 cells. Representative images showing immunofluorescence labeling of HER2 (green) in SNU216 and MKN7 cells. Nuclei were counterstained by Hoechst (blue). Scale bars: 10 μm.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Pertuzumab Enhances the Antitumor Activity of T-DXd in HER2-Positive Gastric Cancer Cells
Immunofluorescence of HER2 in SNU216 and MKN7 cells. Representative images showing immunofluorescence labeling of HER2 (green) in SNU216 and MKN7 cells. Nuclei were counterstained by Hoechst (blue). Scale bars: 10 μm.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S2 from Pertuzumab Enhances the Antitumor Activity of T-DXd in HER2-Positive Gastric Cancer Cells
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Pertuzumab Enhances the Antitumor Activity of T-DXd in HER2-Positive Gastric Cancer Cells
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S9 from Pertuzumab Enhances the Antitumor Activity of T-DXd in HER2-Positive Gastric Cancer Cells
Uncropped western blot related to Figure 5E. Representative uncropped blots showing the expression of p-HER3, HER3, p-AKT S473, and AKT in OE19 and NCI-NB87 cells for 48 h with the following treatments: lane 1, 0 ng/mL T-DXd, 0 μg/mL pertuzumab, and 0 nM NRG1; lane 2, 200 ng/mL T-DXd, 0 μg/mL pertuzumab, and 0 nM NRG1; lane 3, 0 ng/mL T-DXd, 2 μg/mL pertuzumab, and 0 nM NRG1; lane 4, 0 ng/mL T-DXd, 0 μg/mL pertuzumab, and 1.5 nM NRG1; lane 5, 200 ng/mL T-DXd, 0 μg/mL pertuzumab, and 1.5 nM NRG1; lane 6, 0 ng/mL T-DXd, 2 μg/mL pertuzumab, and 1.5 nM NRG1; lane 7, 200 ng/mL T-DXd, 2 μg/mL pertuzumab, and 1.5 nM NRG1. The corresponding Vinculin loading controls are shown in Figure 2E.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S9 from Pertuzumab Enhances the Antitumor Activity of T-DXd in HER2-Positive Gastric Cancer Cells
Uncropped western blot related to Figure 5E. Representative uncropped blots showing the expression of p-HER3, HER3, p-AKT S473, and AKT in OE19 and NCI-NB87 cells for 48 h with the following treatments: lane 1, 0 ng/mL T-DXd, 0 μg/mL pertuzumab, and 0 nM NRG1; lane 2, 200 ng/mL T-DXd, 0 μg/mL pertuzumab, and 0 nM NRG1; lane 3, 0 ng/mL T-DXd, 2 μg/mL pertuzumab, and 0 nM NRG1; lane 4, 0 ng/mL T-DXd, 0 μg/mL pertuzumab, and 1.5 nM NRG1; lane 5, 200 ng/mL T-DXd, 0 μg/mL pertuzumab, and 1.5 nM NRG1; lane 6, 0 ng/mL T-DXd, 2 μg/mL pertuzumab, and 1.5 nM NRG1; lane 7, 200 ng/mL T-DXd, 2 μg/mL pertuzumab, and 1.5 nM NRG1. The corresponding Vinculin loading controls are shown in Figure 2E.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S8 from Pertuzumab Enhances the Antitumor Activity of T-DXd in HER2-Positive Gastric Cancer Cells
Uncropped western blot related to Figure 5B. Representative uncropped blots showing the expression of NRG1 in OE19, and NCI-N87 cells. The corresponding Vinculin loading controls are shown in Figure 5B.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S8 from Pertuzumab Enhances the Antitumor Activity of T-DXd in HER2-Positive Gastric Cancer Cells
Uncropped western blot related to Figure 5B. Representative uncropped blots showing the expression of NRG1 in OE19, and NCI-N87 cells. The corresponding Vinculin loading controls are shown in Figure 5B.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Pertuzumab Enhances the Antitumor Activity of T-DXd in HER2-Positive Gastric Cancer Cells
Uncropped western blot related to Figure 1C. Representative uncropped blots showing the expression of p-EGFR, EGFR, p-HER2, HER2, p-HER3, HER3, p-HER4, HER4, and TOP1 in MKN1, AGS, KATOIII, NUGC3, SNU1, SNU601, NUGC4, SNU16, SNU216, MKN7, OE19, and NCI-N87 cells. The corresponding Vinculin loading controls are shown in Figure 1C.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Pertuzumab Enhances the Antitumor Activity of T-DXd in HER2-Positive Gastric Cancer Cells
Uncropped western blot related to Figure 1C. Representative uncropped blots showing the expression of p-EGFR, EGFR, p-HER2, HER2, p-HER3, HER3, p-HER4, HER4, and TOP1 in MKN1, AGS, KATOIII, NUGC3, SNU1, SNU601, NUGC4, SNU16, SNU216, MKN7, OE19, and NCI-N87 cells. The corresponding Vinculin loading controls are shown in Figure 1C.